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A b s t r a c t
Toxoplasm a gondii is a  cyst-fo rm ing  p a ra site  o f  
c lin ica l re levance in h um ans p r im a rily  because o f  the  
n euro log ic  a b n o rm a litie s  il can cause. In  som e c lin ica l 
circum stances, it is des ira b le  lo d e lec l the p a thogen  
directly. We m o d ifie d  a  com m ercia lly  ava ilab le  
Toxoplasm a p o lym era se  chain  reaction  (P C R ) probe  
capture a ssa y  b y  incorpora ting  u racil N -g lyco sy la se  
( U N G ) lo  p reven t ca rryo ver a m p licon  con tam ina tion .
In  addition , U N G  inactiva tion  a n d  D N A  dena tura tion  
w ere a cc o m p lish e d  chem ica lly  to  s im p lify  the D N A  
hybrid iza tion  lo the capture probe. T he incorpora tion  o f  
U N G  effec tive ly  e lim in a te d  ca rryo ver con tam ina tion ;  
the p ro b e  capture a ssa y  sh o w e d  a  log increase in 
d etec tion  sen sitiv ity  co m p a red  w ith  s ta n d a rd  agarose  
g e l electrophoresis. To a ssess  sen sitiv ity  a n d  p o ssib le  
inh ib ition  o f  am plifica tion , d ifferen t sa m p le  types w ere  
sp ik ed  w ith  Toxoplasm a organism s. A fte r  D N A  
extraction  a n d  P C R  am plifica tion , a  sen sitiv ity  o f  2 
tachyzo ites f o r  the a ssa y  w as d e term in e d  in bu ffered  
saline, cerebrosp ina l f lu id  (C SF), serum , a n d  a m n io tic  
f lu id ;  2 0  tach yzo ites  f o r  w ho le  b lood; a n d  2 0 0  
tachyzo ites f o r  brain  tissue. A n  a d d itio n a l 2 0  hum an  
serum  a n d  C S F  sa m p les  su b m itted  f o r  Toxoplasm a 
sero log ic  testing  w ere run b y  the P C R  m ethod . O f  these, 
on ly  an  Ig M -p o sitive  C S F  sa m p le  w a s P C R  positive.
The  Toxoplasm a P C R  probe  cap ture a ssa y  sh o w ed  
g o o d  se n sitiv ity  a n d  w as no t su b sta n tia lly  in h ib ited  by­
severa l d ifferen t c lin ica lly  re levant sam ples.
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Toxoplasmosis is one of the most common pathogenic 
parasites of humans, infecting 30% to 50% of the world 
population . 1 It is found mostly in warm, moist areas, but 
distribution is worldwide. Animal studies show that Toxo­
plasm a gondii proliferates locally at the site of entry and 
quickly disseminates throughout the body by the way of the 
circulatory system. The organisms are obligate intracellular 
pathogens and most likely are carried within infected leuko­
cytes, but dormant cysts have been observed within most 
tissues of the body of infected persons. The organisms that 
are found free in the plasma or other extracellular fluids prob­
ably have been released recently from infected cells. 1 The 
most common and least invasive diagnostic methods for 
detecting toxoplasmosis are now antibody-based. Toxoplasma 
antibody detection tests are performed by most laboratories 
with commercially available immunoassays, and results can 
be useful indicators that a person has been infected with the 
parasite. Detection of Toxoplasma antibodies, however, indi­
cates infection at some indeterminate time and not neces­
sarily acute or current infection. In many instances in the 
diagnosis of infectious diseases, it is desirable to detect the 
pathogen or its DNA directly.2 These include infections in 
patients with AIDS that cannot be diagnosed reliably by sero­
logic testing because of severe immune system dysfunction. 
A polymerase chain reaction (PCR) assay also could be an 
effective test for prenatal diagnosis of fetal or neonatal toxo­
plasmosis, infections in patients after transplantation, and in 
the diagnosis of ocular toxoplasmosis.3"6 The development of 
a sensitive test that avoids reliance on antibody measurement 
thus would be an important diagnostic tool for use in patients 
with immune deficiency in which serologic tests are unreli­
able and in congenital infections in which early diagnosis is 
important for treatment and management.7' 9
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The use of single DNA template amplification by the 
PC.R process has required the adoption of strict laboratory 
practices to avoid false-positive reactions. A prim ary 
source of false-positive reactions has been identified as 
amplified product (amplicon) carryover from previous reac­
tions. 10 To ensure that amplicons from previous amplifica­
tions could not be ream plified, a carryover prevention 
system was incorporated into a com m ercially available 
Toxoplasma  PC.R probe capture enzyme immunoassay . 11 
This was performed by substituting deoxyuridine triphos­
phate (dUTP) for deoxythymidine triphosphate (dTTP) and 
the addition of UNG to the master mix . 10 To protect dUTP- 
containing product, UNG must be inactivated chemically or 
by heat before the PC.R product can be analyzed further. In 
the present study, UNG inactivation and DNA denaturation 
was accomplished chemically by the addition of a sodium 
hydroxide solution, since it has been shown that UNG is 
not completely inactivated by heat. The buffering capacity 
of the immunoassay hybridization buffer also was adjusted 
to ensure pH neutralization of the chemically treated ampli­
fied product on addition to the probe capture microtiter 
plate.
Once the PC.R protocol incorporating the UNG/dUTP 
system was optimized, the sensitivity of the probe capture 
system was compared with standard gel electrophoresis 
with ethidium bromide staining.
To assess the sensitivity of the Toxoplasma PC.R assay, 
as w ell as p o ss ib le  in h ib itio n  o f a m p lif ica tio n , the 
following sample types were spiked with log-fold dilutions 
of Toxoplasma  organisms: buffered saline, cerebrospinal 
fluid (C.SF), serum, amniotic fluid, whole blood, and brain 
tissue cortex. A mock clinical study was performed by 
spiking a total of 52 C.SF and amniotic fluid samples with 
varying levels of Toxoplasma organisms. PC.R testing also 
was performed on 23 serum, C.SF, and cord blood samples 
submitted for serologic testing for Toxoplasma antibody.
M aterials and Methods
PCR Test
A 193-base-pair product of the 35-fold repetitive B l  
gene of the RH strain of T  gondii was amplified using the 
following primers. TX2 5<?-3<? (TC.T TTA AAG C.GT TC.G 
TGG TC.) and TX4 5<?-3<? (GGA ACT GCA TCC. GTT CAT 
GAG ) . 2 The amplification reactions were performed using 
Amplitaq DNA polymerase, GeneAmp dNTPs (deoxynucle- 
oside triphosphates) with dUTP, and AmpErase UNG (all 
from Perkin Elmer, Foster City C.A). For a 50-nL PCR reac­
tion, the following volumes were used: 21.5 deionized 
w ater; 5 |iL  10- PCR B uffer II; 1 |jL each o f dATP
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(deoxyadenosine triphosphate; 10-mmol/L concentration), 
dC.TP (deoxycytidine triphosphate; 10-mmol/L concentra­
tion), dGTP (10-mmol/L concentration), and dUTP (20- 
mmol/L concentration); 2.5 ^L each of the primers TX2 (5- 
Umol/L concentration) and TX4 (5-nmol/L concentration); 
0.25 nL Amplitaq; 4 ^L magnesium chloride (25-mmol/L 
concentration); 0.25 ^L AmpErase UNG; and 10 ^L of 
template. PCR reactions were performed by using an auto­
mated thermocycler (Perkin Elmer 2400 or 9600). An initial 
cycle of 10 minutes at 50 C. was used to allow UNG to 
excise uracil from any contaminating dUTP-containing prod­
ucts. This was followed by a 10-minute cycle at 95 C. to 
cleave the uracil and inactivate the UNG. Amplification was 
then continued for 40 cycles, each cycle consisting of a 30- 
second denaturation step at 95 C, a 30-second annealing step 
at 55 C, and a 45-second elongation step at 72 C.
Detection of Amplicon
Amplicon detection was performed by standard agarose 
gel electrophoresis and a probe capture immunoassay. For 
the sensitivity and gel comparison studies, samples were 
electrophoresed for 30 to 45 minutes at 80 V on standard 
1.5% agarose gels with ethidium bromide staining. For probe 
capture o f the am plicon, the G en-e ti-k  DNA enzym e 
immunoassay (Diasorin Diagnostics, Stillwater, MN) was 
used. This kit consists of a generic system containing all the 
necessary buffers and substrates and one 96-well strepta- 
vidin-coated plate to which any biotin-labeled capture probe 
can be attached. Hybridized amplicons are detected by an 
anli-double-stranded DNA antibody conjugate. Diasorin also 
offers Toxoplasm a-specific reagents to be used with the 
generic kit, which include primers, a biotin-labeled capture 
probe, and a positive control complementary sequence. For 
the present study, we synthesized our own capture probe 
(5Cbiotin-GCT GGC. GAA AAG TGA AAT TC.A TGA 
GTA TCT-3<0, and p ositive  con tro l com plem entary  
sequence 5<?-3<? (AGA TAC TC.A TGA ATT TC.A C.TT TTC. 
GCC. AGC). The assay was performed as follows: Immedi­
ately after the last PCR cycle, 5 ^L of a 2-mol/L concentra­
tion of sodium hydroxide was added to the 50-nL PCR 
a m p lifica tio n . O ne hundred  m ic ro lite rs  o f  m odified  
hybridization buffer then was added to the microtiter plate 
containing the bound capture probe. The hybridization buffer 
was m od ified  by ad ju stin g  the 
tris(hydroxymethyl)aminomethane (Tris) concentration to a 
64-mmol/L concentration and the pH to 7.0 to allow the 
addition of 2 0  ^L of the denatured amplicon directly to the 
plate. This eliminated the procedure suggested by Diasorin 
of heating the samples for an additional 15 minutes at 95 C. 
followed by an immediate dip into an ice bath. After the 
addition of amplicon, the plate was incubated for 60 minutes 
at 50 C. to allow hybridization of the amplicon to the capture
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probe. The plate then was washed, and 100 of mouse 
monoclonal antibody to double-stranded DNA was added, 
and the plate was incubated for 30 minutes at room tempera­
ture. After another wash, 100 of enzyme tracer (protein A 
conjugate to horseradish peroxidase) was added and incu­
bated for another 30 minutes at room temperature. A third 
wash was then performed followed by the addition of 1 0 0  ^L 
of substrate solution and another 30-minute room temperature 
incubation. Finally, the reaction was stopped with 200 of 
sulfuric acid, and the plate was read on a spectrophotometer 
at a wavelength of 450 nm. The cutoff value was calculated 
by adding 0.150 to the mean optical density (OD) of the 2 
negative assay controls. If the OD is greater than this sum, 
then hybridization has taken place, and the sample result is 
considered positive.
DNA Isolation
DNA was isolated from  sam ples using the Q iagen 
QIAamp System (Qiagen, Valencia, CA), which specifically 
binds nucleic acids to a silica-gel membrane in a centrifuge- 
compatible spin column. Contaminants and PCR inhibitors 
are washed through, and DNA is eluted using 70 C. water. A 
sample volume of 2 0 0  was used per extraction.
Positive Controls, Spiking, and Clinical Samples
Positive control material was obtained from 2 sources. A 
T  g o n d ii  p a rasite  DNA co n tro l was pu rchased  from  
Advanced Biotechnologies (AB1; Columbia, MD). This 
consisted of 100 of isolated DNA obtained from a cell 
culture of 1.0 • 1010 tachyzoites per milliliter. The second 
source was Yeager RH Strain purchased from American 
Type Culture Collection, Rockville, MD (catalog no. 50174).
For the mock clinical spiking and sensitivity studies, 
cultured tachyzoites at a concentration of 1.0 • 109/mL were 
obtained from Gull Laboratories, Salt Lake City, UT. For 
sensitivity and inhibition studies, log dilutions from 1 .0  • 1 0 6 
to 1 .0  • 1 0 1 tachyzoites per m illiliter were made in the 
following sample types: buffered saline, C.SF, serum, amni- 
otic fluid, whole blood, and brain tissue. For sensitivity 
studies, the calculated number of organisms introduced into 
the DNA extraction column was used. Hence, of a spiked 
sample containing 1 • 1 0 2 ( 1 0 0  organisms) per milliliter, only 
2 0 0  nL ( 2 0  organisms) went into the extraction column. 
Therefore, if this sample tested positive, the sensitivity was 
stated as 20 tachyzoites. To further study the sensitivity and 
specificity of the probe capture assay, 26 C.SF and 26 amni- 
otic fluid samples were spiked with varying levels of Toxo­
plasma  organisms ranging from 0  to 2 , 0 0 0  tachyzoites.
The association between serologic and PCR results also 
was studied by collecting and testing 23 samples submitted 
to our laboratory for Toxoplasma serologic testing. These 
included 14 serum, 7 C.SF, and 2 cord blood samples from
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males and females ranging in age from 3 weeks to 54 years.
Results
The substitution of dUTP for dTTP and the addition of 
UNG into the master did not adversely affect the sensitivity 
of the PCR assay. In fact, when both the dUTP-UNG and 
dTTP reactions were optimized, a log increase in sensitivity 
from 2 0  to 2  tachyzoites was observed by the probe capture 
plate with the dUTP-UNG system.
To assess the ability of UNG to protect against cany- 
over, log dilutions of the AB1 DNA standard equivalent to 1 • 
1 0 8 to 1 • 1 0 3 tachyzoites per milliliter were amplified with 
dUTP but no UNG. Amplification was confirmed for each 
dilution, and 10 ^L (for a 50-^L reaction) of each log dilu­
tion then was added back into 1 master mix containing both 
dUTP and UNG and 1 mix containing only dUTP. When 
these mixtures were reamplified, no specific product was 
detected in the UNG-containing mix even up to the highest 
concentration of 1 • 1 0 8 tachyzoites per milliliter, while a 
specific product was amplified from all concentrations of the 
dUTP-only master mix.
The addition of 5 ^L of a 2-mol/L concentration of 
sodium hydroxide to the PCR product after amplification 
proved to be a simple and effective method for the inactiva­
tion of residual UNG and the denaturation of the DNA 
necessary for hybridization to the capture probe. Increasing 
the Tris concentration of the hybridization buffer to 64 
mmol/L at a pH of 7.0 allowed the addition of the denatured 
amplicon directly to the micrometer plate for the hour-long 
hybridization step. The modified hybridization buffer had a 
buffering range allowing ± 50% pipetting error (± 2.5 mL) of 
a 2-m ol/L  concentration of sodium  hydroxide w ithout 
affecting the hybridization of the amplified product to the 
probe.
The sensitivity for the detection of amplified product 
between the probe capture plate and standard 1.5% agarose 
gel with ethidium bromide staining was determined 2  ways. 
First, the AB1 DNA standard was diluted in buffered saline 
to the equivalent of 2 0 0 , 0 0 0  tachyzoites and then amplified 
in the dUTP-UNG system. Dilutions of 1:5 to 1:160 then 
were made of this amplified product and run by both probe 
capture and agarose gel. Probe capture showed positive 
hybridization at a 1:100 dilution (OD, 0.403 with a cutoff of 
0.153) compared with a questionable or faint band at a 1:10 
dilution on the agarose gel IFigure II (lane 4). All subse­
quent dilutions were negative by gel detection (Figure 1, 
lanes 6 -8 ) The second method was performed by spiking 
buffed saline with the AB1 DNA standard in log dilutions of
200,000 to 2 tachyzoite DNA equivalents. Whole blood was
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Dilution of Amplified Product
IFigure I I  Sensitivity comparison of the probe capture plate 
(A) to agarose gel detection (B) of diluted amplicon. The 
probe capture plate shows positive hybridization down to a 
1:100 dilution of amplicon (OD, 0.403; cutoff, 0.153), while 
the gel shows faint bands at 1:5 and 1:10 dilutions, lanes 3 
and 4, respectively. Lane 1, biomarker; lane 2, neat 
amplicon; lanes 5-9, dilutions of amplicon 1:20, 1:40, 1:80, 
1 :1 0 0 , and 1:160, respectively.
spiked in the same fashion with actual T  gondii organisms. 
The DNA from these spiked samples then was extracted by 
using the Qiagen procedure and amplified by PCR. With a 
cutoff OD of 0.181 for this run, positive hybridization was 
seen in spiked buffer (OD, 1.680) and whole blood (OD, 
0.389) down to a level equivalent to 20 tachyzoites by the 
probe capture plate. By agarose gel, a questionable or faint 
band was visualized at 2 0  tachyzoites for spiked buffer and 
the organism spiked blood IFigure 21 (lane 2).
To assess sensitivity and possible inhibition of amplifi­
cation, different sample types were spiked with Toxoplasma 
organisms. The lowest concentration of tachyzoites in which 
positive probe hybridization was observed was considered
the detection sensitivity. After DNA extraction and PCR 
amplification, the results indicated that as few as 2  tachy­
zoites can be detected by positive probe hybridization from 
buffered saline (OD, 1.153), CSF (OD, 0.907), serum (OD,
0.765), and amniotic fluid (OD, 2.012). The sensitivity for 
whole blood (OD, 1.471) was 20 and for brain tissue (OD,
0.289) was 200 tachyzoites ITable II. The adjusted cutoff for 
these runs (as described in the “Materials and M ethods” 
section) was an OD of 0.191. Sufficient volumes of vitreous 
fluid were not available for spiking studies; however, a 
v itreous fluid sam ple from  a 6 6 -year-old w om an was 
submitted to our laboratory specifically for PCR testing. 
Physical exam ination had revealed eye findings highly
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IFigure 21 Sensitivity comparison of the probe capture plate (A) to agarose gel detection of the DNA standard (B) and spiked 
whole blood (C). Positive hybridization was seen on the probe capture plate at a concentration equivalent to 20 tachyzoites 
for the DNA standard (OD, 1.680) and whole blood (OD, 0.389) with a cutoff OD of 0.181. With the agarose gel, only very 
faint questionable bands were observed at the 20-tachyzoite concentration (lane 2). Lane 1, biomarker; lanes 3-7, tachyzoite 
concentrations of 2 0 0 ,0 0 0 , 2 0 ,0 0 0 , 2 ,0 0 0 , 2 0 0 , and 2 , respectively; lane 8 , water, negative control.
consistent with Toxoplasm a  chorioretinitis, and the PCR 
result was positive. For a mock clinical study, 21 C.SF and 21 
amniotic fluid samples each were spiked with the following 
levels of Toxoplasma organisms: 3 of each sample type with
2 , 0 0 0  tachyzoites and 6  of each sample type with 2 0 0 , 2 0 , 
and 2 tachyzoites. An additional 5 samples of each type were 
not spiked, for a total of 42 positive and 10 negative samples. 
When the detection limit was set at 2 tachyzoites, 35 of the
42 spiked samples were PC.R-positive giving a sensitivity of 
83%. All 10 samples that were not spiked were PCR nega­
tive, resulting in a specificity of 100% ITable 21. This 
resulted in an overall agreement of 8 6 %. All 7 of the PCR 
false-negative results were spiked at the 2 tachyzoite level; 5 
were amniotic fluid and 2 were C.SF. When the detection 
limit was set at 20 tachyzoites, all 30 of the C.SF and amni­
otic fluid spiked samples were positive by PCR yielding a
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■Table II
Probe Capture Results of Sensitivity Studies of Relevant 
Sample Types Spiked With Toxoplasma gondii Organisms
Sam ple Type/No. o f Tachyzoites OD R esult
Buffered saline
2 0 0 ,0 0 0 3.030 Positive
2 ,0 0 0 2.642 Positive





2 0 0 ,0 0 0 2.432 Positive
2 0 ,0 0 0 2.573 Positive
2 ,0 0 0 2.456 Positive





2 0 0 ,0 0 0 2.643 Positive
2 ,0 0 0 2.643 Positive





2 0 0 ,0 0 0 2.563 Positive
2 0 ,0 0 0 2.348 Positive
2 ,0 0 0 2.266 Positive





2 0 0 ,0 0 0 2.877 Positive
2 ,0 0 0 2.649 Positive
2 0 0 2.257 Positive
20 1.673 Positive
2 2 .012 Positive*
0 0.061 Negative
Brain cortex
2 0 0 ,0 0 0 1.816 Positive
2 0 ,0 0 0 1.043 Positive
2 ,0 0 0 1.912 Positive




* Positive cutoff. OD. 0.191.
■Table 21
Comparison of Toxoplasma Diasorin* Capture Assay Results 
With Spiked Cerebrospinal and Amniotic Fluid Samples
No. o f Sam ples







* Gen-eti-k DNA enzyme immunoassay, Diasorin Diagnostics, Stillwater, MN.
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sensitivity of 100%. The overall agreement also increased to 
100%, with a specificity of 100% (Table 2).
O f the 23 serum , CSF, and cord b lood  sam ples 
submitted for serologic testing, 10 were positive for IgM, 
IgG, or both to Toxoplasma. Nine of these samples were 
serum; 2 were IgG- and IgM-positive, 2 were IgM-positive 
and IgG-negative, and 5 were IgM-positive but were not 
tested for IgG antibodies. The other positive result was for a 
CSF sample from a 1-month-old boy with high IgM and IgG 
antibody levels. This was the only sample submitted for 
serologic testing that was positive for Toxoplasma by PCR.
Discussion
The incorporation of dUTP and UNG into the master 
mix was an effective way of controlling carryover contami­
nation. Studies showed that contaminant amplicon from the 
equivalent of 1 • 1 0 8 tachyzoites per milliliter could be made 
unamplifiable in new PCR reactions. This procedure could 
be accomplished by implementing minor changes in the 
standard PCR protocol: the substitution of dUTP for dTTP, 
the addition of UNG to the master mix, and two 10-minute 
heat cycles of 50 C and 95 C before standard temperature 
cycling. This procedure, however, is effective only in 
c o n tro llin g  co n tam in a tio n  from  p rev ious reac tio n s 
containing dUTPs; contamination from DNA containing 
native dNTPs will still amplify. The substitution of dUTP for 
dTTP did not adversely affect the efficiency of the PCR reac­
tion, as a log increase in sensitivity was gained by the incor­
poration of dUTP in our application. It has been noted in the 
literature, however, that amplification of longer targets ( 1 -2  
kilobases) is less efficient with dUTP than with dTTP. 10
Although UNG is a heat-labile enzyme and should be 
inactivated by the heat denaturation steps in normal tempera­
ture cycling, 10 it seems that residual active UNG may remain 
even after a 10-minute incubation at 95 C. For these reasons, 
the supplier of UNG (Perkin Elmer) recommends that the 
annealing temperature used for the PCR amplification should 
be at or above 55 C, the temperature at which UNG loses 
activity. In addition, it is recommended that after the final 
PCR cycle, samples should be held at 72 C in the thermo­
cycler and then immediately stored at -20  C or chemically 
treated to prevent degradation of the amplicon by residual 
UNG.
We found that the addition of sodium hydroxide to the 
postamplification PCR product was a simple and effective 
way to inactivate any residual UNG. This also accomplished 
denaturation of the DNA necessary for hybridization to the 
probe capture plate.
The Diasorin immunoassay procedure called for a final 
PCR incubation cycle of 15 minutes at 94 C to denature the
Am J Clin Pathol 2000;113:714-721 719
M artins e t al / PCR Probf Capture Assay for the Detection of Toxoplasma gondii
DNA, followed by an immediate dip of the samples into an 
ice bath, before addition to the probe capture plate. We 
thought this was cumbersome and not practical in a clinical 
setting and that it did not fully address the potential of 
residual UNG activity. By adjusting the buffering capacity 
and pH of the supplied hybridization buffer, we were able to 
add the chemically treated amplicon directly to the probe 
capture plate.
Using a probe capture assay for end product detection, 
instead of a standard agarose gel, resulted in a log increase in 
detection sensitivity. This was seen most clearly when the 
amplicon itself was diluted and assayed (Figure 1). When log 
dilutions of the DNA standard and tachyzoites were spiked 
directly into samples, extracted, and then assayed, the probe 
capture plate showed clear detection at the 2 0 -tachyzoite 
level, while the gel showed questionable very faint bands at 
this level (Figure 2). The advantage of the probe capture 
system is that it has a defined cutoff value and is not influ­
enced by subjective interpretation of faint gel bands, since a 
semiquantitative OD result is obtained. The disadvantage to 
this gain in sensitivity is that a gel band can be visualized in 
as little as 30 to 45 minutes, while the immunoassay takes
3.5 hours to complete all the necessary incubation, washing, 
and reagent addition steps. Based on a run size o f 12 
patients, a cost analysis (including supplies, reagents, and 
labor for sample preparation, extraction, PCR amplification, 
and amplicon detection) was $48.82 per patient for gel detec­
tion and $54.97 per patient for probe capture. Indirect costs, 
including quality control, freight charges, and supervisor and 
professional review, add another $5.25 per patient. In addi­
tion, a 15% PCR royalty fee is charged, adding another 
$16.50 for a total cost of $76.72 per patient for probe capture 
and $70.57 for gel detection. Therefore, the cost per patient 
resulting from using the probe capture plate was $6.15 more 
than standard gel detection.
The PCR immunoassay showed good sensitivity for 
several relevant sample types, especially from buffered 
saline, CSF, serum, and amniotic fluid, in which as few as 2 
tachyzoites could be detected. For whole blood, the sensi­
tivity dropped 1 log to 2 0  tachyzoites, and a 2 -log loss in 
sensitivity (200 tachyzoites) was seen with brain tissue. This 
loss in sensitivity probably was due to inhibitors in these 
sample types or decreased extraction efficiency.
The mock clinical study using CSF and amniotic fluid 
showed that samples spiked down to 2 0  tachyzoites could be 
detected 100% of the time. Of the 12 samples spiked at the 2 
tachyzoite level, 5 were detected, yielding a positivity rate of 
41.7%. Testing of the false-negative samples was repeated 
once using the same DNA extraction and once again after re- 
extracting the original sample, but results for all 7 samples 
remained negative. These false-negative results seemed to be 
due to inhibition by the sample at low organism copy levels,
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as results for all 7 of these samples were positive when 
respited with higher concentrations of T  gondii.
In the present study, there seems to be little correla­
tion between PCR and serologic results, as none of the 9 
IgG- and/or IgM -antibody positive serum samples were 
PCR-positive. This lack of correlation is probably because T  
gondii is an obligate intracellular pathogen that is unlikely to 
be detected in the serum or plasma unless there is a severe 
systemic infection. Alternatively, as in studies of Lyme 
disease, the appearance of antibody may preclude the detec­
tion of an organism’s DNA in whole blood or serum . 12 For 
these reasons, it is likely that other infected closed body 
fluids, such as amniotic fluid, CSF, and vitreous, may be 
more suitable sample types for PCR testing.
The use of a probe capture system for PCR amplicon 
detection proved to be a more sensitive and subjective 
method than standard agarose gel electrophoresis. The cost 
of the probe capture plate was only $6.15 more than gel 
detection and would be even less for larger run sizes in 
which multiple gels would be required. The incorporation of 
a dUTP-UNG system proved effective in eliminating carry­
over even when reactions were contam inated with high 
concentrations of amplicon. This system did not require 
much modification of standard nonprotected PCR protocols 
and could be implemented in probe capture and gel detection 
systems. The assay also demonstrated good sensitivity for 
detecting T  gondii spiked into several relevant sample types.
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